Paratek Pharmaceuticals Inc expected to post a loss of 35  cents a share - Earnings Preview

Paratek Pharmaceuticals

03/05/2022 03:04

* Paratek Pharmaceuticals Inc  PRTK.OQ   PRTK.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 4. 
    * The Boston Massachusetts-based  company is expected to
report  a
65.3% increase in revenue to $27.15 million from $16.43 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Paratek
Pharmaceuticals
Inc is for a loss of 35 cents per share. For the same quarter
last year, the company reported a loss of 39 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 20.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $17.5​, above​ its last closing price
of $2.24. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.62       -0.41      -0.66     Missed  -60
 Sep. 30 2021  -0.44       -0.45      -0.37     Beat    17.8
 Jun. 30 2021  0.35        0.32       0.20      Missed  -36.5​
 Mar. 31 2021  -0.40       -0.38      -0.39     Missed  -2.1
 ​​Dec.        -0.12       -0.04      -0.60     Missed  -1,233
 31 2020                                                .3
 Sep. 30 2020  -0.61       -0.61      -0.46     Beat    24.6​
 Jun. 30 2020  -0.23       -0.06      -0.53     Missed  -748
 Mar. 31 2020  -0.88       -0.80      -0.66     Beat    17.8
 This summary was machine generated May 3 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated